Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.

ABSTRACT:

Importance

Modern immuno-oncology agents have generated great excitement because of their potential to provide durable survival for some patients. However, there is concern regarding the cost of cancer care, and multiple frameworks have been developed to assess value. The American Society of Clinical Oncology (ASCO) framework awards bonus points if substantial durable survival is demonstrated.

Objective

To assess whether modern immuno-oncology agents reach defined efficacy thresholds in value frameworks.

Design, setting, and participants

In this analysis, all US Food and Drug Administration (FDA) approvals for immuno-oncology agents between March 2011 and August 2017 were reviewed. Data required for the ASCO framework were collected, specifically improvement in propor

SUBMITTER: Ben-Aharon O 

PROVIDER: S-EPMC5885826 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature